The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets
Open accessAbstract
Chronic kidney disease (CKD) is a major public health issue. At the histological level, renal fibrosis is the final common pathway of progressive kidney disease irrespective of the initial injury. Considerable evidence now indicates that renal inflammation plays a central role in the initiation and progression of CKD. Some of the inflammatory signaling molecules involved in CKD include: monocyte chemoattractant protein‐1 (MCP‐1), bradykinin B1 receptor (B1R), nuclear factor &kgr;B (NF‐&kgr;B), tumor necrosis factor‐&agr; (TNF&agr;), transforming growth factor &bgr; (TGF‐&bgr;), and platelet‐derived growth factor (PDGF). Multiple antifibrotic factors, such as interleukin‐10 (IL‐10), interferon‐&ggr; (IFN‐&ggr;), bone morphogenetic protein‐7 (BMP‐7), hepatocyte growth factor (HGF) are also downregulated in CKD. Therefore, restoration of the proper balance between pro‐ and antifibrotic signaling pathways could serve as a guiding principle for the design of new antifibrotic strategies that simultaneously target many pathways. The purpose of this review is to summarize the existing body of knowledge regarding activation of cytokine pathways and infiltration of inflammatory cells as a starting point for developing novel antifibrotic therapies to prevent progression of CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Ai, J., Nie, J., He, J., Guo, Q., Li, M., Lei, Y., Liu, Y., Zhou, Z., Zhu, F., Liang, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040363 · Cited by 79
RetractedElseweidy, M. M., Askar, M. E., El-Swefy, S. E., & Shawky, M. (2017) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-017-2631-0 · Cited by 24
RetractedRegulation of the Voltage Gated K+ Channel Kv1.3 by Recombinant Human Klotho Protein
Almilaji, A., Honisch, S., Liu, G., Elvira, B., Ajay, S. S., Hosseinzadeh, Z., Ahmed, M., Munoz, C., Sopjani, M., & Lang, F. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368472 · Cited by 5,592
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Non-Transgenic Mouse Models of Kidney Disease
Rabe, M., & Schaefer, F. (2016) · Nephron · doi:10.1159/000445171 · Cited by 1,922
Cellular and molecular mechanisms of renal fibrosis
Liu, Y. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.149 · Cited by 1,446
Zeisberg, M., Hanai, J.-I., Sugimoto, H., Mammoto, T., Charytan, D., Strutz, F., & Kalluri, R. (2003) · Nature Medicine · doi:10.1038/nm888 · Cited by 1,346
Renal fibrosis: New insights into the pathogenesis and therapeutics
Liu, Y. (2006) · Kidney International · doi:10.1038/sj.ki.5000054 · Cited by 1,089
Cited by
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2
Stenvinkel, P., Chertow, G. M., Devarajan, P., Levin, A., Andreoli, S. P., Bangalore, S., & Warady, B. A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.04.023 · Cited by 297
Peng, X., Wang, Y., Li, H., Fan, J., Shen, J., Yu, X., Zhou, Y., & Mao, H. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1483-7 · Cited by 183
Self-citationRole of MCP-1 as an inflammatory biomarker in nephropathy
Liu, Y., Xu, K., Xiang, Y., Ma, B., Li, H., Li, Y., Shi, Y., Li, S., & Bai, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303076 · Cited by 93
Asiaticoside inhibits renal fibrosis development by regulating the miR‐142‐5p/ACTN4 axis
Zhang, M., Liu, S., Fang, L., Wang, G., & Yin, L. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2110 · Cited by 7
Retracted
Metadata
- Authors
- Lv, W., Booz, G. W., Wang, Y., Fan, F., & Roman, R. J.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 820
- Pages
- 65-76
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2772570025
- Cited by
- 338
- References
- 150
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.